The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Genmab; Gradalis; Immunogen; Merck; Merck; Novocure; Oncolytics; OncoMed; OncXerna Therapeutics; Regeneron; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Immunogen (Inst); Johnson & Johnson; Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Domenica Lorusso
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup
 
Carol Aghajanian
Consulting or Advisory Role - Abbvie; AstraZeneca/Merck; Eisai; Eisai; Mersana; Repare Therapeutics; Roche; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Andrew Dean
Consulting or Advisory Role - A2A Pharmaceuticals; Precision Oncology; Shire; Specialised Therapeutics
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
 
Johanne I Weberpals
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
 
Andrew R. Clamp
Consulting or Advisory Role - AstraZeneca; Eisai Europe; GlaxoSmithKline
Speakers' Bureau - Clovis Oncology
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Immunogen (Inst); Merck (Inst); Pfizer (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Giovanni Scambia
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro
Speakers' Bureau - Clovis Oncology; MSD
 
Alexandra Leary
Honoraria - Medscape
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst); PEGASCY; Tesaro (Inst); zentalis
Research Funding - Inivata (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Robert W. Holloway
Consulting or Advisory Role - Abbvie
Speakers' Bureau - AstraZeneca; Bard/Davol; Clovis Oncology; Eisai; GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Genelux
 
Margarita Amenedo Gancedo
Consulting or Advisory Role - PharmaMar
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD/AstraZeneca; PharmaMar; Tesaro/GSK
Travel, Accommodations, Expenses - Lilly; Roche
 
Peter C.C. Fong
Consulting or Advisory Role - MSD; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Jeffrey C. Goh
Stock and Other Ownership Interests - ICON Cancer Care; Immutep
Honoraria - Ipsen; MSD Oncology
Consulting or Advisory Role - BMS; GlaxoSmithKline; Janssen Oncology; MSD
Speakers' Bureau - AstraZeneca/MedImmune; BMS; Ipsen; Janssen; MSD Oncology
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Arcus Biosciences; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; InxMed; Iovance Biotherapeutics; Janssen Oncology; Laekna Therapeutics; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; Novocure; Onconova Therapeutics; OncoQuest; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sutro Biopharma; Takeda; Tarveda Therapeutics; Tesaro; Toray Industries; Translational Genomics Research Institute; VBL Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Sandra M. Goble
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Lara Maloney
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Jonathan A. Ledermann
Consulting or Advisory Role - Amgen; Artios; AstraZeneca/MedImmune; Clovis Oncology; Eisai; GlaxoSmithKline UK Ltd.; Merck; Tesaro; VBL Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Pfizer; Tesaro/GSK
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst)
Other Relationship - Regeneron